Business context and reporting period
Phathom Pharmaceuticals, Inc. filed its Form 10-K for the fiscal year ended December 31, 2020. The company is a clinical-stage biopharmaceutical developer with no approved products or product revenue; its business is currently centered on vonoprazan, a potassium-competitive acid blocker licensed from Takeda for the United States, Europe, and Canada.
Financial and operating performance
- Revenue and margins: No product revenue was reported. Profitability and operating margins are not meaningful while the company remains pre-commercial.
- Full-year results: Research and development expense was $98.1 million (up $77.8 million year over year); general and administrative expense was $27.5 million (up $20.6 million). Total operating expenses were $125.7 million and net loss was $129.1 million, versus $106.2 million and $255.1 million, respectively, in 2019. Basic and diluted net loss per share was $3.88, compared with $22.45.
- Q4 results (unaudited): Operating expenses were $52.4 million, including $41.7 million of R&D and $10.8 million of G&A; net loss was $53.7 million ($1.58 per share). Q4 2019 net loss was $98.0 million, but included substantial noncash fair-value charges.
- Cash flow: Net cash used in operating activities was $69.7 million in 2020, compared with $36.5 million in 2019. Investing activities used $1.0 million; financing activities provided $114.5 million. Cash and cash equivalents increased by $43.7 million to $287.5 million.
- Liquidity and debt: Working capital was $235.8 million. The company had $50.0 million of term-loan principal outstanding; debt was recorded at $47.0 million net of discount. Contractual debt payments, including estimated interest and final payment fee, totaled $61.6 million. Management estimated cash would fund operations into Q4 2022, subject to execution and spending assumptions.
Material changes versus prior periods
- R&D spending rose sharply as the pivotal Phase 3 program advanced. G&A increased with hiring and prelaunch commercial preparation.
- The 2020 net loss was lower than 2019 largely because 2019 included $96.3 million of warrant-liability fair-value expense and $49.5 million of convertible-note fair-value expense. The 2019 results also included $78.9 million of acquired in-process R&D expense for the Takeda license.
- Operating cash use increased by $33.2 million. The company raised $88.8 million net from a December 2020 stock offering and borrowed an additional $25.0 million under its term-loan facility.
- Q4 2020 operating expenses and net loss increased versus Q3 2020, with quarterly net loss rising from $34.1 million to $53.7 million.
Outlook, commentary, and key risks
- PHALCON-HP enrollment was completed in January 2021 and PHALCON-EE enrollment in November 2020. Management expected top-line results for H. pylori in Q2 2021 and erosive esophagitis in the second half of 2021; contingent on positive results, planned U.S. submissions were H2 2021 and H1 2022, respectively.
- The company planned to begin a Phase 2 on-demand NERD study in 2021. Prior vonoprazan NERD studies did not meet their primary endpoints, an important uncertainty for this expansion program.
- COVID-19 caused a temporary pause in new-patient randomization from March to June 2020. Further pandemic-related disruption could affect trials, supply, costs, and financing.
- Vonoprazan had not been approved in the company’s licensed territories. Approval, trial outcomes, market uptake, pricing and reimbursement, and the timing of commercialization remain uncertain. The company expects to build its own U.S. commercial operation and seek partners for Europe and Canada.
- Manufacturing is outsourced. Takeda’s Hikari facility had received an FDA warning letter relating to aseptic manufacturing; the company reported no clinical supply constraint but said unresolved issues could affect facility approval. Sandoz is contracted to supply and package antibiotics for planned H. pylori convenience packs.
- FDA review of requested QIDP designations for amoxicillin-capsule combinations remained pending. Existing designations apply to specified tablet combinations; a different commercial formulation could affect exclusivity benefits or timing.
- The Takeda license includes up to $250 million in sales milestones and tiered royalties in the low double digits to mid-teens. Term loans are secured by substantially all company assets other than intellectual property and certain other assets.
- Postmarketing safety information from Japan included very rare serious reactions for which causality could not be ruled out. The company also identified risks from competition, patent protection, third-party dependence, and the need for additional financing.
Important facts for investors to verify
- Final PHALCON-HP and PHALCON-EE results, including whether they support the proposed filings and the breadth of any label.
- Actual cash burn, commercial-preparation costs, and whether the stated Q4 2022 cash runway remains achievable.
- FDA status of manufacturing sites and the requested QIDP designations for capsule-based combinations.
- Supply readiness and minimum-purchase commitments under the Takeda and Sandoz agreements, alongside the company’s loan covenants and repayment schedule.
- Emerging safety data, market-access and reimbursement prospects, and evidence supporting the commercial opportunity relative to generic therapies.